全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

Metronidazole Induced Liver Injury: A Rare Immune Mediated Drug Reaction

DOI: 10.1155/2013/568193

Full-Text   Cite this paper   Add to My Lib

Abstract:

Drug induced liver injury (DILI) can result either from dose-dependent direct hepatotoxicity or from an unpredictable dose-independent idiosyncratic reaction. Incidence of idiosyncratic DILI is estimated to be approximately 10–15 per 100,000 patient years. Here we report an extremely rare case of metronidazole induced delayed immune-allergic hepatocellular liver injury masquerading as autoimmune hepatitis. A previously healthy 54-year-old Caucasian male, who was treated with metronidazole for Clostridium difficile associated diarrhea, presented 3 months later with right upper quadrant abdominal pain. Laboratory tests revealed total bilirubin level of 12.7?mg/dL, direct bilirubin of 7.2?mg/dL, alanine aminotransferase (ALT) of 973?IU/L, aspartate transaminase (AST) of 867?IU/L, alkaline phosphatase (AP) of 96?IU/L, and an INR of 1.9, suggestive of hepatocellular pattern of injury. A detailed workup for hepatitis revealed no other etiology. A clinical diagnosis of metronidazole induced liver injury was made. With a persistent rise in his bilirubin and transaminase levels, the patient was started on oral prednisone. At the 2-week posthospitalization follow-up visit, the patient reported a significant improvement in his overall sense of being well and liver functions tests trended down substantially (total bilirubin 7.2?mg/dL, ALT 420?IU/L, AST 276?IU/L, AP 183?IU/L, and INR 1.5). 1. Introduction Reactive chemical metabolites formed during hepatic drug metabolism can incite hepatocellular damage from oxidative stress and mitochondrial dysfunction causing drug induced liver injury (DILI). DILI can result from either dose-dependent direct hepatotoxicity (e.g., acetaminophen toxicity) or from an unpredictable dose-independent idiosyncratic reaction. Genetic polymorphisms in the drug bioactivation and detoxification pathways along with host immunological factors are responsible for these rare and potentially fatal idiosyncratic DILI [1]. Of the several mechanisms proposed to elucidate the mechanism underlying immune-allergic idiosyncratic DILI, the “hapten hypothesis” is the most favored [2]. Drugs and/or their metabolites covalently bind to host proteins forming drug-protein adducts (i.e., haptens) that are processed by the antigen-presenting cells and trigger a T-cell mediated cytotoxicity or B-cell antibody response. Incidence of idiosyncratic DILI is estimated to be approximately 10–15 per 100,000 patient years [3]. About 1 in 7 cases of acute liver failure are related to an adverse drug reaction, making DILI the most common indication for liver

References

[1]  D. E. Amacher, “The primary role of hepatic metabolism in idiosyncratic drug-induced liver injury,” Expert Opinion on Drug Metabolism and Toxicology, vol. 8, no. 3, pp. 335–347, 2012.
[2]  S. Tujios and R. J. Fontana, “Mechanisms of drug-induced liver injury: From bedside to bench,” Nature Reviews Gastroenterology and Hepatology, vol. 8, no. 4, pp. 202–211, 2011.
[3]  L. N. Bell and N. Chalasani, “Epidemiology of idiosyncratic drug-induced liver injury,” Seminars in Liver Disease, vol. 29, no. 4, pp. 337–347, 2009.
[4]  G. Ostapowicz, R. J. Fontana, F. V. Schio?dt et al., “Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States,” Annals of Internal Medicine, vol. 137, no. 12, pp. 947–954, 2002.
[5]  N. Chalasani, R. J. Fontana, H. L. Bonkovsky et al., “Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States,” Gastroenterology, vol. 135, no. 6, pp. 1924–1934, 2008.
[6]  M. I. Lucena, R. J. Andrade, N. Kaplowitz et al., “Phenotypic characterization of idiosyncratic drug-induced liver injury: The influence of age and sex,” Hepatology, vol. 49, no. 6, pp. 2001–2009, 2009.
[7]  E. Bj?rnsson, H. Nordlinder, and R. Olssson, “Metronidazol as a probable cause of severe liver injury,” Hepato-Gastroenterology, vol. 49, no. 43, pp. 252–254, 2002.
[8]  W. M. Lee, L. S. Hynan, L. Rossaro et al., “Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure,” Gastroenterology, vol. 137, no. 3, pp. 856–864, 2009.
[9]  A. Giannattasio, M. D'Ambrosi, M. Volpicelli, and R. Iorio, “Steroid therapy for a case of severe drug-induced cholestasis,” Annals of Pharmacotherapy, vol. 40, no. 6, pp. 1196–1199, 2006.
[10]  E. Bj?rnsson and L. Davidsdottir, “The long-term follow-up after idiosyncratic drug-induced liver injury with jaundice,” Journal of Hepatology, vol. 50, no. 3, pp. 511–517, 2009.

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133